Pfizer, Inc. (PFE) has been a topic of discussion on Reddit, particularly regarding its RSV vaccine, ABRYSVO, which has been approved by the FDA for high-risk adults under 60. This approval is significant as it expands the vaccine's availability beyond the previously eligible groups, potentially increasing its market reach. However, some Reddit users have noted that pharmacies are still primarily vaccinating those over 60 or pregnant, suggesting a lag in the implementation of the new guidelines. One user advised checking with insurance providers to ensure coverage, as this could be a barrier to access for some individuals.
In another Reddit thread, discussions veered towards Gelteq, a company partnered with Pfizer, highlighting its innovative gel-based drug delivery system. While the focus was on Gelteq's potential growth and partnerships, Pfizer's involvement was noted as a significant endorsement of Gelteq's technology. This partnership could enhance Pfizer's product offerings, particularly in the realm of drug delivery solutions, although the primary focus of the discussion was on Gelteq's market potential and upcoming catalysts.
Pfizer's stock is currently priced at $26.16, reflecting a slight increase of 0.23% from the previous close.